GS 4104 neuraminidase inhibitor: Phase III

GILD partner F. Hoffmann-La Roche Ltd. presented data from a U.S. Phase III treatment study of GS 4104 in 629 patients, showing a 30 percent reduction in illness. Median disease duration was 2.9 days in both the 75 mg (p=0.0001) and 150 mg (p=0.001)

Read the full 443 word article

How to gain access

Continue reading with a
two-week free trial.